INC. ANNOUNCES PALO ALTO HEADQUARTERS
ALTO, Calif. – Dec, 2000 – Pharmagenesis, Inc., an Orchid group venture
company, announces its Palo Alto, Calif. headquarters.
The laboratories and offices act as central operations for the company,
the heart of Orchid group’s research and development activities.
mission is to develop new pharmaceuticals based on the bioactive substances
found in Traditional Chinese Medicine (TCM), aimed at both the Eastern and
company believes that by focusing research on TCM, there is a significant
likelihood of finding new effective therapeutic products with excellent safety.
Pharmagenesis will screen Chinese pharmacopoeia, select drug candidates
for further research and develop selected candidates for Western markets.
In addition, Pharmagenesis will develop importation of selected Western
drugs in China through the company’s Beijing operations.
Valley gives the company access to top research and pharmaceutical scientists as
well as close proximity to many pharmaceutical corporations,” Nicolas Druz,
chairman of the board and CEO, Pharmagenesis, said.
“Palo Alto also acts as an easy port of debarkation for our Asia
has selected the organ systems responsible for immune responses and generation
of blood cells as its initial research focus.
company’s offices and laboratory facilities occupy 10,000 square feet. Currently there are more than 30 scientists and
administrative staff in the Palo Alto location.
Of that total, ten are Ph.D.’s and/or M.D.’s.
Alto-based Pharmagenesis, Inc. develops novel pharmaceutical and nutra-ceuticals
derived from herbal remedies employed in traditional Chinese medicine, a
tradition that spans over 4,000 years of use.
Established in 1991, the privately held company is focused on treatments
for cancer therapy-related bone-marrow suppression and for the management of
transplant rejection. Through its
operations in Beijing, Suzhou and Taipei, these and other products are being
commercialized in the high-growth markets of China and Taiwan.